Novel perspectives for influenza vaccine formulation and administration. L. Lactis cell wall derived adjuvant stable dry powder vaccines and mucosal vaccine delivery
PhD ceremony: Mr. V. Saluja, 11.00 uur, Academiegebouw, Broerstraat 5, Groningen
Thesis: Novel perspectives for influenza vaccine formulation and administration. L. Lactis cell wall derived adjuvant stable dry powder vaccines and mucosal vaccine delivery
Promotor(s):prof. H.W. Frijlink
Faculty: Mathematics and Natural Sciences
In his thesis Vinay Saluja presents successful strategies to optimize influenza vaccine formulations, which can be implemented in the future to improve protection against influenza. Vaccination is seen as the most effective way for controlling influenza. However, currently available influenza vaccines have some serious drawbacks like: (i) limited protection against infection, (ii) limited stability as the vaccine have shelf life of one year at 4 °C, and (iii) administration by injection. Therefore, new technologies have to be implemented in order to tackle these problems. Sulaja used a novel adjuvant, Gram-positive enhancer (GEM; Lactococcus lactis cell wall derived adjuvant) particles to improve the quality and quantity of the immune response of influenza vaccines. Furthermore, he evaluated different drying techniques to improve the vaccine stability and to develop dry powder vaccine for needle-free administration.
Influenza vaccine mixed with GEM particles administered via the intramuscular route potentiated as well as improved the quality of immune response, resulting in at least 5 fold decrease of the antigen dose. Moreover, Saluja showed that combination of the GEM particles and vaccine strongly improved the quality of immune responses after intranasal immunization.
Moreover, a dry and stable (20 °C/3years) powder for influenza vaccine was developed by Sulaja for inhalation using spray drying and spray freeze drying. Pulmonary immunization with the powders resulted in improved immune responses compared to standard intramuscular vaccines. Furthermore, he developed a freeze-dried powder formulation for H5N1 (bird flu) vaccine, which was stable for one year at 20 °C.
Last modified: | 13 March 2020 01.14 a.m. |
More news
-
18 July 2024
Smart robots to make smaller chips
A robotic arm in a factory that repeatedly executes the same movement: that’s a thing of the past, states Ming Cao. Researchers of the University of Groningen are collaborating with high-tech companies to make production processes more autonomous.
-
17 July 2024
Veni-grants for ten researchers
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to ten researchers of the University of Groningen and the UMCG. The Veni grants are designed for outstanding researchers who have recently gained a PhD.
-
15 July 2024
Funding for RUG researchers from National Growth Fund programme Circular Plastics NL
For research on making plastics circular, Professors Patrizio Raffa and Katja Loos together receive about 1.2 million euros from the National Growth Fund programme Circular Plastics NL.